Tiêu đề 2. Ky nguyen moi trong dieu tri suy tim voi EF duoi muc binh thuong - GS. Akshay Desai Suvas.pdf ✅

This presentation was prepared with the support of Novartis. References are provided by the speaker upon request. FA -11253847
Akshay S. Desai, MD, MPH Director, Cardiomyopathy and Heart Failure Advanced Heart Disease Section Cardiovascular Division Brigham and Women’s Hospital Boston, MA A New Era in Treatment of Heart Failure with EF below Normal This presentation was prepared with the support of Novartis. References are provided by the speaker upon request FA-11253847
Disclosures • I have received honoraria for consulting from Alnylam, Abbott, AstraZeneca, Avidity Biopharma, Axon Therapeutics, Biofourmis, Bayer, Cytokinetics, GlaxoSmithKline, Medpace, Merck, New Amsterdam, Novartis, Parexel, Regeneron, River2Renal, Roche, Veristat, Verily • I have received research funding from Alnylam, AstraZeneca, Abbott, Bayer, and Novartis
Objectives • Highlight the evidence base and urgency for application of 4-drug medical therapy for HFrEF • Review recent updates in major HFrEF guidelines from ESC and ACC/AHA/HFSA • Explore potential benefits of HFrEF therapies in HF with mildly reduced EF